Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”…
Year: 2023
Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2 at the 2023 ARVO Annual Meeting
Data demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization (CNV) lesions…
Green Water Labs Introduces Algae Control, a Revolutionary Eco-Friendly Solution to Prevent and Eliminate Unwanted Algae Growth
SEATTLE, April 26, 2023 (GLOBE NEWSWIRE) — Green Water Labs, a leading manufacturer of eco-friendly…
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
European Commission Approval of Opfolda and Commercial Launch of Pombiliti®+ Opfolda®Anticipated in…
CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people…
G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
RESEARCH TRIANGLE PARK, N.C., April 26, 2023 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX),…
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly…
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis”…
tru Independence Adds $1B Family Office Seven Mile Advisory
Multifamily office taps tru for ability to support existing clients while enabling growth PORTLAND, Ore.–(BUSINESS…
Helios Technologies Promotes Rick Martich to President of Hydraulics, Americas
SARASOTA, Fla.–(BUSINESS WIRE)–Helios Technologies, Inc. (NYSE: HLIO) (“Helios” or the “Company”), a global leader in…
Valmont Industries, Inc. Announces Partnership With Peerless-AV
OMAHA, Neb.–(BUSINESS WIRE)–Valmont® Industries, Inc., a global leader that provides vital infrastructure and advances agricultural…
As Generative AI Drives Urgency for AI Regulations, Most Companies Unprepared for New Requirements: Verta Insights Study
MENLO PARK, Calif.–(BUSINESS WIRE)–#ai–Verta, the Operational AI company, today previewed findings from the 2023 AI…
Citizens Business Conditions Index™ Bounces Back in Q1
Respondents seeing revenue increases broadly despite possible recession risk PROVIDENCE, R.I.–(BUSINESS WIRE)–#CBCI–Citizens announced today that…
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ:…
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ:…
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Primary analysis of NATALEE, the first and only positive Phase III study of a CDK4/6…
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Primary analysis of NATALEE, the first and only positive Phase III study of a CDK4/6…
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company…
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company…
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO),…